Grifols Crosses the Leverage Finish Line, but China Albumin Misses the Pace

A sub-4x balance sheet and 59% free-cash-flow jump are real; the albumin recovery slip and a 2027 IPO wait are the catch.

GRF.MC · Earnings Call · 2026-11-02

The quarter that finally crossed the line

Grifols' Q3 2026 was, on the surface, the clean execution quarter management has been promising. Revenue reached €2.04bn, up 8.4% at constant currency, led by Biopharma's 10.3% growth. Adjusted EBITDA was €538m, margin 26.4%, up 60bp, and nine-month free cash flow before M&A hit €298m, up 59% year on year. The balance-sheet headline was bigger: total net leverage fell to 3.98x, secured leverage 2.5x, with €2.14bn liquidity. That is down from 5.5x in June 2024. Rahul Srinivasan did not bury it: “our credit agreement leverage is now finally below 4x” — Rahul Srinivasan, Chief Financial Officer · 2026-11-02. The credit agreement milestone and cash conversion improvement are the real change this quarter, not the revenue line. But the quality of the beat needs a second look. Q3 Biopharma benefited from phasing-related gains and a strong Rabies season, and Rahul explicitly warned: “given the phasing-related gains that have benefited our Q3 Biopharma results, please expect more modest Biopharma growth in Q4” — Rahul Srinivasan, Chief Financial Officer · 2026-11-02. So the quarter is better than the run-rate; management is not asking investors to annualize it. The operating story is intact, but Q4 is a slower, tougher comparison.

China albumin: the apology tour

The uncomfortable part is albumin. Q3 albumin revenue fell 13.2% at constant currency, and nine-month albumin was down 13.9%. Management blamed Chinese regulatory restrictions and elevated channel inventories. In July, they had expected the market to stabilize in H2. Now the language has changed.

When we last updated you in July, we expected market conditions to stabilize during the second half of the year. What we are seeing now is that the adjustment is taking longer than anticipated, particularly as the market continues to work through elevated channel inventories.
Jose Ignacio Abia Buenache, Chief Executive Officer · 2026-11-02

That is a clear push-out. The China albumin problem is not new; what is new is the admission that H2 will not be the inflection. Management now points to 2027 for more stability, and even then only if inventories flush. The contrast with the prior call is stark. In July, Rahul said: “what I was referencing was the absolute level for H2, rather than the growth rate. So please do not reflect any draconian scenarios.” — Rahul Srinivasan, CFO or Financial Officer (inferred from context) · 2026-07-28 The base was supposed to hold. It hasn't. The elevated inventories have persisted, and the early signs of improvement in sell-out have not translated into sell-in. This is the single biggest reason the equity story is not a clean recovery. Importantly, Grifols is responding by managing the mix, not chasing volume. IG grew 11.3% in Q3, with Subcutaneous IG up 40.3%, and Alpha-1/Specialty Proteins up 18.2%. But management said it constrained IG growth to protect last-liter economics and will pursue a similar value-oriented strategy in coming quarters. That is a mature plasma company choosing margin over top-line. It also caps the revenue upside if albumin stays weak.

Egypt is the margin lever, but not yet

The strategic answer to both cost and supply is Egypt. Collections are scaling: monthly volumes nearly doubled since the start of the year, 18 centers are operating, 20 by Q1 2027, and the company is targeting roughly 1m liters in 2026 and ultimately 3m liters annually. The EMA approval lets Egyptian plasma enter the global network, and management argues the country has structurally attractive collection cost and higher protein yields. This is the goal of plasma self sufficiency evolving into an integrated derived medicine platform. But the P&L impact is still mostly ahead. Rahul said: “You will begin to see much greater impact of Egypt as in '27 and certainly as Egypt ramps up even greater in the years in '28 and '29.” — Rahul Srinivasan, Chief Financial Officer · 2026-11-02 That is consistent with July, when management said the full impact of the 1m liters would come through in 2027 and dismissed execution risk: “we do not anticipate any execution risks with that ramp up.” — Rahul Srinivasan, CFO or Financial Officer (inferred from context) · 2026-07-28 So Egypt remains a long-duration margin story, not a Q3 earnings driver. It supports the medium-term case but does not fix the current albumin hole.

The deferred value-unlock and the new regulatory noise

The other pillar is the potential IPO of the U.S. Biopharma business. It was announced earlier this year as a value-unlock process. On this call, Rahul pushed the timeline: “I do not expect an update on the IPO until 2027.” — Rahul Srinivasan, Chief Financial Officer · 2026-11-02 That is a deferral, not a cancellation, but it removes a near-term catalyst. In Q1, management was already constrained: “we are in the initial phases of the consideration of the potential IPO and therefore, there is no further information we can comment on at this time.” — Jose Ignacio Abia Buenache, Chief Executive Officer · 2026-05-09 The difference now is the explicit 2027 date. There was also a new question on regulatory scrutiny. Alvaro Lenze asked about publications regarding increased scrutiny by European agencies. Nacho Abia downplayed it as industry-wide, not Grifols-specific: “This is not focused on Grifols by any mean. It's across the entire industry.” — Jose Ignacio Abia Buenache, Chief Executive Officer · 2026-11-02 He framed adverse events as part of the IG indication and an ongoing dialogue with EMA and FDA. That may be true, but it introduces a headline risk the call had not carried before. In a sector where clinical evidence and safety are the currency, even an industry-wide review can pressure sentiment.

What actually changed

The story is not "Grifols is fixed." It is "Grifols fixed the balance sheet faster than it fixed albumin." The leverage milestone and free-cash-flow conversion are genuine and hard-earned. But the growth mix is narrowing: IG and Specialty are carrying the quarter, albumin is still shrinking, and Diagnostics is declining because of the QuidelOrtho joint-business dissolution, even if underlying Diagnostics grew 2.3%. Management is deliberately throttling IG to protect margin, which is sensible but limits the top line. For the equity, the next 12 months hinge on four things: China albumin destocking into 2027, Egypt cost benefits scaling from 2027, SPARTA data late this year with a Q1 2027 presentation, and any IPO update. The value creation case now leans more on cost, mix and cash than on a broad revenue recovery. That is a better story than the leverage crisis of 2024. It is not yet the growth story the multiple would need.